Role of recombinant factor VIIa in the treatment of intractable XXXX in vascular surgery.

@entity1 @entity1755 @entity548 @entity2334 @entity86 @entity130
BACKGROUND: Most recent publications have shown that the recombinant form of activated factor VII (rFVIIa; NovoSeven, Novo Nordisk A/S, Bagsv  rd, Denmark) induces excellent hemostasis in @entity1 with severe intractable @entity548 caused by @entity130 and major surgery. The purpose of this study was to determine the influence of rFVIIa on the treatment of intractable perioperative @entity548 in vascular surgery when conventional hemostatic measures are inadequate. MATERIALS AND METHODS: There were two groups of @entity1 : the NovoSeven group (group N), 10 @entity1 with @entity1755 ( @entity1755 ) and 14 @entity1 operated on due to @entity2334 ( @entity2334 ); the control group (group C), 14 @entity1 with @entity1755 and 17 @entity1 with @entity2334 . All @entity1 suffered intractable @entity548 refractory to conventional hemostatic measures, while @entity1 from group N were additionally treated with rFVIIa. RESULTS: @entity86 was significantly lower in group N treated with rFVII (P < .0001). Postoperative administration of packed red blood cells, fresh frozen plasma, and platelets was lower in @entity1 from group N, (P < .0001). Successful @entity548 arrest was reported in 21 @entity1 (87.5%) treated with rFVIIa, and in 9 @entity1 (29.03%) in group C (P < .001). Thirty-day mortality in these two groups significantly differed. The mortality rate was 12.5% (3 @entity1 ) in group N and 80.65% (25 @entity1 ) in group C (P < .0001). CONCLUSION: Our findings suggest that rFVIIa may play a role in controlling the intractable perioperative and @entity86 in surgical @entity1 undergoing a repair of @entity1755 and @entity2334 . Certainly, prospective randomized trials are necessary to further confirm the efficacy and cost-effectiveness of rFVIIa in these @entity1 .
